Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens is a PHASE1 clinical asset sponsored by Medigene AG in Acute Myeloid Leukemia. SEO and diligence focus: WT1/PRAME vaccination, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.